Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

NCT05029960 is registered in ClinicalTrials.gov with University of Rochester as lead sponsor.

NCT NCT05029960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05029960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas
Lead sponsor
University of Rochester
Phase
Phase 1
Overall status
Terminated
Start date
May 17, 2022
Completion date
May 9, 2024
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumor